Skip to main content
Signal8

Embecta Corp. (EMBC)

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Instruments & Supplies

Embecta Corp. logo

Embecta Corp.

NASDAQ:EMBCHealthcare
Pre+1.62%$6.29
Close$6.19-2.21%AH$6.19+1.62%since
Mkt Cap$350.72M
Float55.96M
O/S56.66M
Inst Own90.4%
SI10.5%
Div Yield5.17%
Dilution
Embecta Corp. logoNASDAQ:EMBCPre$6.29+1.62%
Pipeline1 lead-sponsored trial·0 active0 completed(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
  • Not applicable
    Withdrawn

    Embecta AID System in Adults With Type 2 Diabetes

    An AID System., Standard of Care (SC)

    Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM) +5

    Enrollment
    0
    Start
    Jan 2025est.
    Primary Completion
    Mar 2026est.
    Completion
    May 2026est.
    NCT06692153
Search ClinicalTrials.gov for “Embecta”